Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022

European Journal of Pharmacology

Volumn 328, Issue 2-3, 1997, Pages 183-189

  Shimazawa, Masamitsu ^a   Takiguchi, Yoshiharu ^a   Umemura, Kazuo ^a   Kondo, Kazunao ^a   Nakashima, Mitsuyoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Arterial thrombosis; Cyclooxygenase; Platelet aggregation; Thromboxane A2

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DALTROBAN; DRUG METABOLITE; PAMICOGREL; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBIN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY BLOOD FLOW; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FEMORAL ARTERY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PHOTOCHEMISTRY; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION;

EID: 0031005718     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)83044-0     Document Type: Article

References (31)

1. Ashida S., Sakum K., Abiko Y. Antithrombotic effects of ticlopidine, acetylsalicylic acid and dipyridamole in vascular shunt model in rats. Thromb. Res. 17:1980;663-671.
2. Born G.V.R., Cross M.J. The aggregation of blood platelets. J. Physiol. 168:1963;178-195.
3. Durante W., Kroll M.H., Vanhoutte P.M., Schafer A.I. Endothelium-derived relaxing factor inhibits thrombin-induced platelet aggregation by inhibiting platelet phospholipase C. Blood. 76:1992;110-116.
4. Edit J.F., Allison P., Norle S., Ashton J., Golino P., Mcnatt J., Buja L.M., Willerson J.T. Thrombin is an important mediator of platelet activation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest. 84:1989;18-27.
5. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA. 86:1989;7585-7589.
6. Gryglewski R.J., Korbut R., Swies J., Kostka-Trabka E., Bieron K., Robak J. Thrombolytic action of ticlopidine: possible mechanisms. Eur. J. Pharmacol. 308:1996;61-67.
7. Heras M., Chesebro J.H., Webster M.W.I., Mruk J.S., Grill D.E., Penny W.J., Bowie E.J.W., Badimon L., Fuster V. Hirudin, heparin, and placebo during deep arterial injury in the pig: the in vitro role of thrombin in platelet-mediated thrombosis. Circulation. 82:1990;1476-1484.
8. 2-receptor antagonist, on arterial thrombosis in guinea pigs. Jpn. J. Pharmacol. 63:1993;521-523.
9. 2, ADP and thrombin in thrombogenesis in the guinea pig. Eur. J. Pharmacol. 231:1993;421-425.
10. Jang I.K., Gold H.K., Ziskind A.A., Leinbach R.C., Fallon J.T., Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibitor. Circulation. 81:1990;219-225.
11. Kawasaki T., Kaku S., Kohinata T., Sakai Y., Taniuchi Y., Kawamura K., Yano S., Takenaka T., Fujimura Y. Inhibition by aurintricarboxylic acid of von Willebrand factor binding to platelet GPIb, platelet retention, and thrombus formation in vivo. Am. J. Hematol. 47:1994;6-15.
12. 2) analog. J. Pharmacol. Exp. Ther. 255:1990;1210-1217.
13. Massad L., Plotkine M., Capdeville C., Boulu R.G. Electrically induced arterial thrombosis model in the conscious rat. Thromb. Res. 48:1987;1-10.
14. Matsuno H., Umematsu T., Umemura K., Takiguchi Y., Wada K., Nakashima M. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator. Br. J. Pharmacol. 106:1992;533-538.
15. Merino J., Livio M., Rajtar G., De Gaetano G. Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation. Biochem. Pharmacol. 29:1980;1093-1096.
16. 2 receptor by 4-(2-(p-chlorobenzene)sulphonylamino)ethylbenzene acetic acid (BM-13505). In: Int. Symp. Leukotrienes Prostanoids Hlth. Dis., Tel Aviv. p. 11.
17. Rao G.H.R. Influence of anti-platelet drugs on platelet-vessel wall interactions. Prostaglandins Leukotrienes Med. 30:1987;133-145.
18. Roth G.J., Calverley D.C. Aspirin, platelets, and thrombosis: theory and practice. Blood. 83:1994;885-898.
19. Savi P., Bernat A., Dumas A., Aït-Chek L., Herbert J.-M. Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells. Thromb. Res. 73:1994;117-124.
20. Schumacher W.A., Heran C.L., Youssef S., Megill J.R., Michel I., Durham S.K. Comparison of a thromboxane receptor antagonist and aspirin in experimental arterial thrombosis. Haemostasis. 23:1993;219-228.
21. Schumacher W.A., Steinbacher T.E., Heran C.L., Megill J.R., Durham S.K. Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Thromb. Haemost. 69:1993;509-514.
22. Smith E.F., McDonald J. Protective effects of the thromboxane receptor antagonists BM 13.177 and BM 13.505 against U 46619-induced sudden death in rats. Pharmacology. 36:1988;340-347.
23. 2 analogues in human platelets. J. Biol. Chem. 265:1990;6836-6844.
24. Takiguchi Y., Hirata Y., Wada K., Nakashima M. Arterial thrombosis model with photochemical reaction in guinea-pig and its property. Thromb. Res. 67:1992;435-445.
25. 2. Thromb. Haemost. 68:1992;460-463.
26. Takiguchi Y., Shimazawa M., Nakashima M. A comparative study of the antithrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea-pigs. Br. J. Pharmacol. 118:1996;1633-1638.
27. Umemura K., Kawai H., Ishihara H., Nakashima M. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat. Jpn. J. Pharmacol. 67:1995;253-258.
28. Vickers J.D. U73122 affects the equilibria between the phosphoinositides as well as phospholipase C activity in unstimulated and thrombin-stimulated human and rabbit platelets. J. Pharmacol. Exp. Ther. 266:1993;1156-1163.
29. 2 and thrombin. Thromb. Haemost. 71:1994;366-374.
30. Yamashita A., Matsuo K., Yokota K., Ito K., Nurimoto S. Anti-platelet effect and mode of action of a new anti-platelet agent KBT-3022. Eur. J. Pharmacol. 183:1990;340.
31. Yokota K., Yamashita A., Oda M. Anti-thrombotic activity of KBT-3022 in experimental models of thrombosis. Jpn. J. Pharmacol. 68:1995;201-206.